Therefore, TMZ resistance was mediated by changes in the main, critical component of the mismatch repair mechanism, mutS homolog 6 (MSH6), particularly in recurrent GBM following TMZ-based radiochemotherapy 54, 55. This evidence concerns the gene MSH6 and glioblastoma.